Atomwise inks China deal as list of AI collaborations lengthens
The long list of major AI biopharma collaborations has gotten longer as one of the first artificial intelligence startups has inked its first deal in China.
San Francisco-based startup Atomwise has signed an agreement to develop targeted drugs with Hansoh Pharmaceuticals, a deal that could ultimately be worth up to $1.5 billion. Hansoh is flush with cash after a $1 billion IPO on the Hong Kong exchange in June.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
